Qol Holdings Co Ltd

Qol Holdings maintains a debt-to-equity ratio of 0.72, indicating a moderate reliance on debt financing, while its liquidity position is characterized as medium. The company's current ratio of 0.81 suggests that its current liabilities exceed its current assets, which could signal potential short-term liquidity challenges. Free cash flow is negative at -7.295 billion JPY, primarily due to capital expenditures of -21.926 billion JPY, which outstrip operating cash flow of 12.594 billion JPY. Profitability metrics show a return on equity (ROE) of 9.04% and a return on assets (ROA) of 3.23%, both below the industry median for drug retailers. The company's net income of 5.165 billion JPY is supported by an operating income of 12.785 billion JPY, but its gross profit margin of 14.8% is in line with the industry average. Geographically, Qol Holdings is concentrated in Japan, with no disclosed international operations. Its revenue is derived from a single business segment focused on drug retailing, with no material diversification across product lines or geographic regions. The company's revenue growth is expected to remain stable, with no significant changes projected in the current or next fiscal year. Historical revenue of 263.972 billion JPY reflects a mature business model with limited expansion opportunities. Risk factors include a medium liquidity risk due to the current ratio below 1 and a negative net cash position after subtracting total debt. Dilution risk is assessed as low, with no recent or planned share issuances that would significantly impact ownership structure. Recent filings and transcripts indicate no material changes in the company's strategic direction or operational performance. Analysts have issued a single "Hold" recommendation with a mean price target of 2,100 JPY, suggesting limited upside potential in the near term.